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Background: Few population-based studies have examined the relationship between glycemic status and chronic
kidney disease (CKD) in China. We examined the prevalence of CKD across categories of glycemia [diagnosed
diabetes, undiagnosed diabetes (fasting plasma glucose [FPG] ≥ 126 mg/dL), prediabetes (FPG 100–126 mg/dL)
and normal glycemia (FPG <100 mg/dL)] among Chinese adults and assessed the relative contribution of dysglycemia
(prediabetes and/or diabetes) to the burden of CKD.
Methods: 5,584 Chinese adults aged 20–79 years were selected from the Pudong New Area of Shanghai through a
multistage random sampling. Demographic and lifestyle characteristics, anthropometry and blood pressure were
measured. Biochemical assays included FPG, serum creatinine and lipids, urinary creatinine and albumin. Prevalence of
albuminuria [urine albumin-to-creatinine ratio (ACR)≥ 30 mg/g], decreased kidney function and CKD (either decreased
kidney function or albuminuria) across levels of glycemia were estimated.
Results: The prevalence of albuminuria, decreased kidney function and CKD each increased with higher glycemic levels
(P < 0.001). Based on the MDRD Study equation, the unadjusted CKD prevalence was 30.9%, 28.5%, 14.1% and 9.2% in
those with diagnosed diabetes, undiagnosed diabetes, prediabetes and normoglycemia, respectively. The corresponding
age-, gender- and hypertension-adjusted CKD prevalence were 25.8%, 25.0%, 12.3% and 9.1%, respectively. In a
multivariable analysis, the factors associated with CKD were hypertension (Odds ratio [OR] 1.70, 95% confidence
interval [CI]: 1.42-2.03), dysglycemia (OR 1.65, 95% CI: 1.39-1.95), female gender (OR 1.48, 95% CI: 1.25-1.75), higher
triglycerides (OR 1.14, 95% CI: 1.08-1.20 per mmol/L), higher body mass index (OR 1.08, 95% CI: 1.05-1.10 per kg/m2),
and older age (OR 1.02, 95% CI: 1.01 -1.03 per year). The population attributable risks (PARs) associated with diabetes,
prediabetes, dysglycemia (diabetes and prediabetes) and hypertension were 18.4%, 19.7%, 30.3% and 44.5% for CKD
as defined by the MDRD study equation, and 15.8%, 24.4%, 29.2% and 10.0% with the CKD-EPI equation. Estimates of
prevalence and ORs of the relative contribution of various risk factors to CKD obtained with the CKD-EPI equation
were similar.
Conclusions: As much as 30% of the CKD burden may be associated with dysglycemia among Chinese adults,
independent of age, gender and hypertension status. Prevention and control of diabetes and prediabetes should be
a high priority in reducing the CKD burden in China.
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Chronic kidney disease (CKD) is increasingly prevalent
worldwide, in developing and developed countries alike
[1], and is associated with a substantial burden of mor-
tality, morbidity and health care costs [2]. Diabetes mel-
litus is a growing pandemic [3] and is the leading cause
of CKD in many countries, contributing to increased
CKD-related morbidity and mortality [4,5]. In the United
States, for example, diabetes accounts for 30 to 40%
of CKD [6]. Furthermore, recent evidence suggests an
increased risk of CKD even in non-diabetic ranges of
glycemia [7,8].
In China, the reported prevalence of CKD ranges from
11.0 to 13.0% depending on geography, and diabetes is a
potential major contributor to this burden [9-12]. China
has the largest number of people living with diabetes in
the world [3], with a national prevalence of diabetes and
prediabetes estimated at 9.7% (92.4 million adults) and
15.5% (148.2 million adults), respectively [13]. Despite
this heavy burden, unlike in some regions of the world
where population-based studies have examined the rela-
tionship between glycemic status and CKD [14-16] as well
as the relative contribution of dysglycemia (prediabetes or
diabetes) to CKD worldwide, very few of such investiga-
tions have been conducted in China [17].
We therefore estimated the prevalence of CKD across
categories of glycemia (diagnosed diabetes, undiagnosed
diabetes, prediabetes, or normal glucose tolerance) and
assessed the relative contribution of dysglycemia to the fre-
quency of CKD in a representative sample of Chinese adult
adults, in the Pudong New Area of Shanghai in China.
Methods
Design and participants
A total of 6,387 adults aged 20 to 79 years and residing
in the Pudong New Area of Shanghai- China, were ran-
domly selected through a three-stage sampling process
to participate in a cross-sectional study conducted be-
tween April and July 2008 [18]. Sampling was conducted
follows. Based on the residents’ average social economic
status, the 30 streets in the Pudong New Area were classi-
fied into three groups (each with 10 streets), and 4 streets
were randomly selected from each of these groups, mak-
ing a total of 12 streets. Then, a total of 34 communities,
which hold about 71,000 eligible residents, were randomly
selected from the 783 communities in the 12 selected
streets. The expected number of participants in each com-
munity was calculated as 9.0% of its eligible population;
and thereafter participants were randomly selected from
households in each of the included community. Pregnant
women, as well as physically or mentally disabled persons
were excluded. Of the 6,387 eligible individuals, 5,584
(87.4%) responded and were interviewed, 804 (12.6%) de-
clined to be interviewed for miscellaneous reasons. Thestudy protocol was approved by Fudan University Insti-
tutional Review Board (IRB00002408, FWA00002399).
Measurements
After obtaining written consent, a structured in-person
interview was conducted by trained personnel to collect
information on demographic factors, history of hyper-
tension, diabetes and dyslipidemia, use of tobacco and
alcohol, physical activity, and family history of hyperten-
sion and diabetes. Blood pressure, body weight, standing
height, and waist and hip circumferences were measured
according to a standardized protocol. Body mass index
(BMI) was calculated as weight in kilograms divided by
height in meters squared (kg/m2) [19], with overweight
defined as an adult BMI ≥24 kg/m2 and obesity ≥28 kg/m2
by the Working Group on Obesity in China [20]. All par-
ticipants provided 10 mL of fasting blood and 50 mL of
morning void urine for biochemical analyses at the Peo-
ple’s Hospital of Shanghai in Pudong New Area. An auto-
matic Biochemical Analyzer (HITACHI 7170A, Hitachi,
Ltd, Tokyo, Japan) was used to measure fasting plasma
glucose (FPG), serum triglycerides (TG), total cholesterol
(TC) and creatinine; urinary concentrations of creatinine
and albumin were measured by enzymology or immunora-
diometry methods. The inter-assay coefficient of variation
was < 1.5% for FPG, < 1.6% for TG, < 3.0% for TC, < 2.1%
for serum creatinine, < 7.0% for urinary album, and < 2.1%
for urinary creatinine.
Definitions
Diagnosed diabetes was defined by the answer “yes” to
the question, “Have you ever been told by a doctor or
other health professional that you have diabetes or sugar
diabetes?” People who answered “no” (n = 3380) or were
uncertain about their status (n = 1852) were classified,
based on FPG, as having either undiagnosed diabetes
(FPG ≥ 126 mg/dL), prediabetes (FPG 100–126 mg/dL)
or normoglycemia (FPG < 100 mg/dL) [21].
Self-reported hypertension was defined by the answer
“yes” to the question, “Have you ever been told by a doctor
or other health professional that you have hypertension or
high blood pressure?” Undiagnosed hypertension was de-
fined as measured systolic blood pressure ≥ 140 mmHg
and/or diastolic blood pressure ≥ 90 mmHg. Prescription
of angiotensin –converting enzyme inhibitors (ACEIs) or
angiotensin II receptor blockers (ARBs) for treating hyper-
tension and CKD was also ascertained by questionnaire.
Hypertension was defined as either self-reported hyperten-
sion (including those under medication) or undiagnosed
hypertension.
Renal function was defined on the basis of estimated
glomerular filtration rate (eGFR), calculated using either
the Modification of Diet in Renal Disease (MDRD) equa-
tion (modified for Chinese adults) or the Chronic Kidney
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The MDRD equation is eGFR (mL/min/1.73 m2) = 175 ×
Calibrated – Scr (mg/dL)−1.234 × age (year) −0.179 [female ×
0.79] [22]. The CKD-EPI equation is eGFR (mL/min/
1.73 m2) = 141 ×min(Scr/ê, 1)á ×max (Scr/ê, 1)-1.209 ×
0.993Age × 1.018 [if female] × 1.159 [if black] [23]; ê is 0.7
for females and 0.9 for males, á is −0.329 for females
and −0.411 for males, min indicates the minimum of Scr/ê
or 1, and max indicates the maximum of Scr/ê or 1.
Decreased kidney function was defined as an eGFR of
less than 60 mL/min/1.73 m2. Microalbuminuria and
macroalbuminuria were defined as a urine albumin–
to -creatinine ratio (ACR, mg/g) between 30 to 299 mg/g
and ≥ 300 mg/g, respectively, according to theAmerican
Diabetes Association (ADA) guidelines [6]. CKD was de-
fined as either decreased kidney function (low eGFR) or
kidney damage (albuminuria) or both [24] Albuminuria
was measured cross-sectionally, hence we used a modi-
fied definition of stages of CKD, which were as follows:
stage 1- kidney damage with normal or increased GFR
(eGFR ≥ 90 mL/min/1.73 m2); stage 2- kidney damage
with mild decreased GFR (eGFR 60 to 89 mL/min/
1.73 m2); stages 3- moderately decreased GFR (eGFR 30 to
59 mL/min/1.73 m2); stages 4 or 5- severely decreased
eGFR or kidney failure (eGFR < 30 mL/min/1.73 m2) [25].
Statistical analysis
Demographic and clinical characteristics were compared
across all four categories of glycemia using the Chi-square
tests for categorical variables, and Kruskal-Wallis tests for
continuous variables that were not normally distributed.
Crude prevalence of CKD, decreased kidney function and
albuminuria by glycemic status were calculated. The preva-
lence of CKD, adjusted for age, gender and hypertension
status by glycemic status, was estimated using multiple
logistic regression. The odds ratios (ORs) and 95% confi-
dence intervals (CIs) of the independent association be-
tween dysglycemia (prediabetes or diabetes) and CKD,
adjusting for age, gender, hypertension status, BMI and
TG, were estimated using logistic regression models. We
used the adjusted ORs to estimate the population attribut-
able risk percent (PAR%), the proportion of the condition/
disease in the population due to the presence of risk factors
or the proportion of the condition/disease in the popula-
tion that would be eliminated if the risk factors for CKD
were removed. The PAR% was calculated for diabetes, pre-
diabetes or both conditions relative to normoglycemia
(used as referent group), using the Levin’s formula [26]:
PAR%= p (r-1)/(p(r-1) +1), where p is the proportion with
diabetes, prediabetes or both conditions and r is the odds
ratio. With the Levin’s formula, PAR% was also calculated
for hypertension relative to normotension (used as referent
group). All statistical analyses were done using SPSS ver-
sion 18 (2010 SPSS Inc; IBM, Chicago, IL).Results
Characteristics of participants by glycemic status
The crude prevalence of diagnosed diabetes, undiagnosed
diabetes, prediabetes, and normal glucose tolerance were
6.3%, 4.9%, 24.6% and 64.2%, respectively. Table 1 shows
the characteristics of participants (n = 5,584- 2,477 males
and 3,107 females) by glycemic status. Compared with
those with prediabetes or normal glucose tolerance, people
with diagnosed or undiagnosed diabetes were more likely
to be older, had a lower education level, be overweight or
obese, and be more-frequent drinkers. Men accounted for
more than half of the population with undiagnosed dia-
betes but for less than half of the other categories of gly-
cemia (P < 0.001, Table 1). Higher levels of height, weight,
TG or TC and lower levels of eGFR (using the MDRD or
CKD-EPI equation) were observed among individuals with
undiagnosed diabetes compared to those with other gly-
cemic status. ACR was higher among those with diagnosed
or undiagnosed diabetes than among those with prediabe-
tes or normoglycemia. The reported percentage of people
taking ACEI/ARBs was overall low, but relatively higher in
those with diagnosed diabetes.
Prevalence of albuminuria, decreased kidney function
and CKD by glycemic status
Table 2 presents data on the prevalence of kidney damage.
The crude prevalence of albuminuria, decreased kidney
function and CKD differed significantly across the glycemic
groups. Albuminuria was present in 28.9% in people with
diagnosed diabetes, 28.1% of those with undiagnosed dia-
betes, 12.9% of those with prediabetes, and 8.7% of those
with normoglycemia (P < 0.001). Regardless of the method
of GFR estimation, those with diabetes or prediabetes had
a higher prevalence of decreased kidney function than
those with normoglycemia (3.5%, 1.8%, 2.6% and 0.9% with
the MDRD Study equation, and 6.1%, 2.9%, 4.1% and 1.6%
with the CKD-EPI equation, for diagnosed, undiagnosed
diabetes, prediabetes and normoglycemia, respectively,
P < 0.001). The unadjusted CKD prevalence using the
MDRD Study equation was 30.9%, 28.5%, 14.1% and 9.2%
in those with diagnosed diabetes, undiagnosed diabetes,
prediabetes and normoglycemia, respectively (P < 0.001).
The prevalence of CKD (at any stage) was significantly
higher in individuals with diabetes or prediabetes than
in those with normoglycemia (P < 0.05). Meanwhile, the
prevalence of CKD stages 1 and 2 was higher than the
prevalence of stage 3 through 5 in individuals across gly-
cemic categories (P < 0.05). Among those with CKD, as
defined by the MDRD equation, 15.2% had diagnosed
diabetes, 11.1% had undiagnosed diabetes and 27.3% had
prediabetes. Similar proportions were observed with the
use of CKD-EPI equation - 15.4%, 10.8% and 27.6% for
diagnosed, undiagnosed diabetes and prediabetes, respect-
ively. With the CKD-EPI equation, the unadjusted CKD
Table 1 Characteristics of participants by glycemic status
Characteristic Glycemic status P
Diagnosed diabetes Undiagnosed diabetes Prediabetes Normoglycemia
n(%) 346 (6.7) 274 (5.3) 1360 (26.2) 3557 (68.5) —
Age (years) 59.0 (53.0,68.0) 57.0 (49.0,65.3) 55.0 (48.0,62.0) 49.0 (37.0,57.0) <0.001
Gender (%) <0.001
Male 46.5 53.3 47.1 42.5
District (%) 0.360
Rural 62.1 55.5 57.9 57.8
Height (cm) 162.0 (155.0,167.1) 162.5 (156.0,170.0) 162.5 (157.0,169.0) 162.0 (157.0,169.0) 0.019
Weight (kg) 65.0 (57.5,73.0) 68.0 (60.0,74.0) 65.1 (58.0,72.5) 61.0 (55.0,69.0) <0.001
FPG (mg/dL) 141.3 (118.4,174.1) 148.3 (134.0,199.8) 106.2 (102.5,111.6) 91.1 (86.8,94.9) <0.001
TG (mg/dL) 186.0 (132.9,292.3) 212.6 (141.7,318.9) 177.1 (115.1,265.7) 141.7 (97.4,212.6) <0.001
TC (mg/dL) 189.5 (162.4,216.6) 197.2 (174.0,224.3) 189.5 (166.3,216.6) 177.9 (154.7,201.1) <0.001
eGFR (ml/min/1.73 m2)
MDRD Study–estimated 107.7 (88.4,125.2) 110.6 (90.4,128.6) 101.1 (87.9,118.6) 108.0 (93.1,125.1) <0.001
CKD-EPI–Estimated 94.9 (81.9,103.6) 96.4 (83.4,106.6) 95.0 (83.6, 103.9) 100.7 (89.5,111.6) <0.001
ACR (mg/g) 13.2 (4.8,37.0) 11.7 (4.8,36.8) 6.9 (2.6,16.5) 5.8 (2.2,12.1) <0.001
BMI (kg/m, %) <0.001
<24 39.0 32.1 41.8 59.7
Overweight, 24- 44.5 47.1 43.2 31.8
Obesity, ≥ 28 16.5 20.8 15.0 8.5
Hypertension (%) 60.3 54.7 36.6 20.9 <0.001
ACEIs/ARBs (%) 1.4 0.7 0.4 0.2 0.002
Education (%) <0.001
Less than high school 72.8 71.9 65.9 56.1
High school or more 27.2 28.1 34.1 43.9
Household income per person year in Yuan (%) 0.398
<12,000 54.9 58.0 56.5 58.6
12,000– 42.5 40.9 40.8 38.7
36,000– 2.0 0.0 2.0 1.8
≥72,000 0.6 1.1 0.7 0.9
Smoking (%) 0.112
Sometimes/not at all 74.0 70.8 77.1 74.9
Every day 26.0 29.2 22.9 25.1
Alcohol drinking (%) <0.001
Nondrinkers 23.2 22.1 27.7 35.2
1-2 drinkers per week 18.9 17.6 15.4 20.0
3-4 drinkers per week 7.4 7.4 12.6 11.0
5-6 drinkers per week 15.8 8.8 7.5 6.6
everyday drinkers 34.7 44.1 36.8 27.2
Data expressed as median (25th, 75th percentile) for continuous variables and percentage for categorical variables. P value for Kruskal-Wallis test (continuous variables) or
χ2 test (categorical variables). Diagnosed diabetes, self-reported of diabetes diagnosis; undiagnosed diabetes, FPG≥ 126 mg/dL and no self-report of diabetes; prediabetes,
FPG≥ 100 and< 126 mg/dL and no self-report of diabetes; no diabetes, FPG < 100 mg/dL and no self-report of diabetes.
Abbreviations: TG Triglyceride, TC Total cholesterol, eGFR Estimated glomerular filtration rate, ACR Albumin-creatinine ratio, CKD-EPI Chronic kidney disease epidemiology col-
laboration, MDRD Modification of diet in renal disease.
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Table 2 Kidney function by glycemic status, with estimation of GFR by the MDRD Study equation and the
CKD-EPI equation
Characteristic Glycemic status P
Diagnosed diabetes Undiagnosed diabetes Prediabetes Normoglyciemia
n Prevalence (95% CI) n Prevalence (95% CI) n Prevalence (95% CI) n Prevalence (95% CI)
Albuminuria (%) 100 28.9 (24.1-33.7) 77 28.1 (22.8-33.5) 176 12.9 (11.2-14.7) 308 8.7 (7.8-9.6) <0.001
Microalbuminuria (%) 81 23.4 (18.9-27.9) 71 26.0 (20.8-31.2) 162 12 (10.3-13.8) 296 8.4 (7.5-9.3) <0.001
Macroalbuminuria (%) 19 5.5 (3.1-7.9) 6 2.2 (0.5-4.0) 14 1.0 (0.5-1.6) 12 0.3 (0.2-0.5) <0.001
MDRD Study–estimated
Decreased kidney function (%) 12 3.5 (1.5-5.4) 5 1.8 (0.2,3.4) 35 2.6 (1.7,3.4) 31 0.9 (0.6,1.2) <0.001
CKD (%) 107 30.9 (26.0-35.8) 78 28.5 (23.1-33.8) 192 14.1 (12.3-16.0) 326 9.2 (8.2-10.1) <0.001
CKD Stage 1 73 6.1 (3.5-8.6) 63 3.7 (1.4-5.9) 113 3.2 (2.3-4.2) 230 1.7 (1.3-2.2) 0.002
CKD Stage 2 21 6.1 (3.5-8.6) 10 3.7 (1.4-5.9) 44 3.2 (2.3-4.2) 62 1.7 (1.3-2.2)
CKD Stage 3 8 2.3 (0.7-3.9) 4 1.5 (0.0-2.9) 33 2.4 (1.6-3.3) 24 0.7 (0.4-0.9)
CKD Stage 4/5 2 0.6 (0.2,1.4) 0 0.0 (0.0-0.0) 0 0.0 (0.0-0.0) 2 0.1 (0.0-0.1)
CKD-EPI–Estimated
Decreased kidney function (%) 21 6.1 (3.5-8.6) 8 2.9 (0.9-4.9) 56 4.1 (3.1-5.2) 58 1.6 (1.2-2.1) <0.001
CKD (%) 114 33.6 (28.5-38.5) 80 29.2 (23.8-34.6) 204 15.2 (13.4-17.2) 342 9.8 (8.8-10.8) <0.001
CKD Stage 1 63 18.2 (14.1-22.2) 52 19.0 (14.3-23.7) 96 7.1 (5.7-8.4) 208 5.9 (5.1-6.6) <0.001
CKD Stage 2 37 10.7 (7.4-14.0) 25 9.1 (5.7-12.6) 80 5.9 (4.6-7.1) 100 2.8 (2.3-3.4)
CKD Stage 3 13 3.8 (1.7-5.8) 3 1.1 (0.2-2.3) 28 2.1 (1.3-2.8) 34 1.0 (0.6-1.3)
CKD Stage 4/5 1 0.3 (0.2-0.9) 0 0.0 (0.0-0.0) 0 0.0 (0.0-0.0) 0 0.0 (0.0-0.0)
Data presented as n, percentage (CI, confidence interval) for categorical variables. P value for χ2 test (categorical variables).
Albuminuria was defined as a urinary albumin-to-creatinine ratio (ACR) >30 mg/g creatinine; Microalbuminuria and macroalbuminuria were defined as a ACR between 30
and 299 mg/g and 300 mg/g or greater, respectively. CKD was defined as estimated glomerular filtration rate(eGFR) < 60 mL/min/1.73 m2 or albuminuria.
Abbreviations: CKD Chronic kidney disease, CKD-EPI Chronic kidney disease epidemiology collaboration, MDRD Modification of diet in renal disease.
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9.8% for diagnosed, undiagnosed diabetes, prediabetes and
normoglycemia, respectively) but showed a similar pattern
across the glycemic categories with slightly more individ-
uals in stage 2 or stage 3 of CKD (Table 2).
Adjustment for age, gender, and hypertension status re-
sulted in a slightly lower CKD prevalence [25.8%, 25.0%,
12.3% and 9.1% for diagnosed diabetes, undiagnosed dia-
betes, prediabetes and normoglycemia, respectively] but
similar patterns across the diabetes categories, using either
the MDRD Study or the CKD-EPI equation (Table 3). In
pair-wise comparisons, the adjusted CKD prevalence using
the MDRD Study equation was higher in those with diag-
nosed diabetes than in those undiagnosed (25.8% vs.
25.0%), and higher in those with prediabetes than in those
with normoglycemia (12.3% vs. 9.1%) (P < 0.008). When
using the CKD-EPI equation, although the adjusted CKD
prevalence appeared lower figures obtained with the
MDRD equation (overlapping confidence intervals), indi-
viduals with diagnosed or undiagnosed diabetes (Table 3)
still had a higher burden of CKD compared to those with
prediabetes or normoglycemia (24.5%, 23.3%, 12.1% and
9.8%, for diagnosed, undiagnosed diabetes, prediabetes and
normoglycemia, respectively).Relative contribution of dysglycemia to the burden of CKD
Figure 1 shows data on the relative contribution of dys-
glycemia (diabetes or prediabetes) and hypertension to
the burden of CKD, through a comparison of the age-
adjusted prevalence of CKD among individuals with only
hypertension, only dysglycemia, both, and neither of these
conditions. Regardless of the equation used to derive
eGFR, the highest age-adjusted CKD prevalence was con-
sistently observed in those with hypertension and dsyglyce-
mia (19.4% in men and 23.5% in women using the MDRD
Study equation; 18.5% in men and 23.8% in women using
the CKD-EPI equation). Those with only hypertension or
only dysglycemia had a lower prevalence of CKD, and those
with neither of these conditions had the lowest prevalence
(P < 0.05). Women had a higher prevalence of CKD than
men, in any of the hypertension and/or dysglycemia groups
(P < 0.05).
As shown in Table 4, MDRD-defined CKD was inde-
pendently associated with hypertension (OR 1.70, 95% CI:
1.42-2.03), dysglycemia (OR 1.65, 95% CI: 1.39-1.95), fe-
male gender (OR 1.48, 95% CI: 1.25-1.75), higher TG (OR
1.14, 95% CI: 1.08-1.20 per mmol/L), higher BMI (OR 1.08,
95% CI: 1.05-1.10 per kg/m2), and older age (OR 1.02, 95%
CI: 1.01 -1.03 per year). Albuminuria was also associated
Table 3 Adjusted prevalence of CKD by glycemic status and selected characteristics, with estimation of GFR by the
MDRD Study equation and the CKD-EPI equation (%)
Characteristic Glycemic status P
Diagnosed diabetes Undiagnosed diabetes Prediabetes Normoglycemia
MDRD Study–estimated
Overall 25.8 (21.0-31.2) 25.0 (19.9-30.9) 12.3 (10.3-14.6) 9.1 (4.2-13.9) <0.001
Age (years)
20-59 23.8 (17.7-31.2) 27.9 (21.0-36.0) 10.4 (8.3-13.0) 7.7 (4.8-9.6) <0.001
≥60 28.5 (21.3-37.0) 22.6 (15.4-31.9) 15.8 (12.0-20.6) 13.1 (6.9-11.6) <0.001
Gender
Male 23.4 (16.9-31.4) 21.1 (14.8-29.1) 8.6 (6.3-11.5) 6.7 (3.1-9.5) <0.001
Female 23.8 (17.9-30.9) 25.5 (18.5-34.2) 14.5 (11.7-17.9) 11.6 (7.0-14.2) <0.001
BMI (kg/m2)
<24 23.3 (16.5-31.8) 22.5 (14.7-32.9) 9.5 (7.0-12.6) 7.1(2.7-14.2) <0.001
Overweight, 24- 25.4 (18.5-33.9) 24.4 (17.2-33.5) 12.5 (9.5-16.2) 11.0(3.6-22.2) <0.001
Obesity, ≥28 27.2 (16.4-41.6) 30.5 (18.8-45.4) 19.4 (13.2-27.5) 18.5(3.5-45.4) 0.002
Hypertension
Yes 35.1 (27.6-43.4) 35.4 (26.6-45.5) 17.3 (13.5-21.8) 16.7 (6.4-36.8) <0.001
No 19.9 (14.0-27.6) 20.1 (14.0-28.0) 10.5 (8.2-13.3) 6.9 (3.4-13.3) <0.001
CKD-EPI–Estimated
Overall 24.5 (20.0-29.7) 23.3 (18.4-29.0) 12.1 (10.2-14.3) 9.8 (5.0-13.8) <0.001
Age (years)
20-59 23.8 (17.7-31.2) 28.0 (21.1-36.1) 10.4 (8.3-13.0) 7.8 (5.0-9.4) <0.001
≥60 33.2 (25.6-41.9) 24.1 (16.7-33.4) 18.7 (14.6-23.7) 15.7 (8.7-14.0) <0.001
Gender
Male 23.5 (17.1-31.4) 20.4 (14.3-28.2) 9.1 (6.8-12.1) 7.3 (3.4-10.4) <0.001
Female 24.4 (18.5-31.5) 24.5 (17.7-32.8) 14.3 (11.5-17.5) 11.7 (7.1-14.4) <0.001
BMI (kg/m2)
<24 23.7 (17.0-32.1) 20.6 (13.3-30.4) 9.4 (7.1-12.4) 7.5 (3.0-15.0) <0.001
Overweight, 24- 25.7 (18.8-34.1) 24.9 (17.7-33.9) 13.0 (10.0-16.8) 11.5 (3.8-23.2) <0.001
Obesity, ≥28 30.4 (18.8-45.1) 30.4 (18.8-45.4) 21.2 (14.7-29.7) 19.5 (3.7-36.8) 0.001
Hypertension
Yes 37.5 (29.8-45.9) 36.9 (28.0-46.8) 18.9 (15.0-23.6) 18.0 (7.1-30.9) <0.001
No 20.8 (14.8-28.4) 19.2 (13.3-26.8) 10.9 (8.6-13.7) 7.5 (3.8-14.2) <0.001
Data presented as percentage (95%CI, confidence interval) for categorical variables. P value for χ2 test (categorical variables). Prevalence estimates were adjusted
for age, gender and hypertension status using multivariable logistic regression, excluding variables being examined (e.g., age-stratified prevalence adjusted for
gender and hypertension status only). CKD was defined as estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 or albuminuria.
Abbreviations: CKD Chronic kidney disease, BMI, Body mass index, MDRD Modification of diet in renal disease, CKD-EPI Chronic kidney disease
epidemiology collaboration.
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http://www.biomedcentral.com/1471-2369/14/253with increased age, female sex, higher BMI, higher TG,
hypertension and dysglycemia, while decreased GFR was
associated with increased age, male sex, and hypertension.
The ORs obtained using the CKD-EPI equation were con-
sistent with the results obtained with the MDRD Study
equation (Table 4). The PAR% for CKD (defined using the
MDRD Study equation) was 18.4%, 19.7%, 30.3% and
44.5% for diabetes, prediabetes, dysglycemia and hyper-
tension, respectively. The corresponding figures of PAR%based on the CKD-EPI equation were 15.8%, 24.4%, 29.2%
and 10.0%, respectively.
Discussion
Our study shows an important contribution of dys-
glycemia to the occurrence of CKD, irrespective of the
approach used to defining CKD. We found that CKD
prevalence, as estimated by low eGFR and/or the pres-
ence of albuminuria, was higher among individuals with
Figure 1 Comparison of age-adjusted prevalence of CKD with estimation of the GFR by the MDRD Study equation and the CKD-EPI
equation, stratified by hypertension or hyperglycemic status. CKD prevalence expressed as mean ± SD. All P values less than 0.05 for ANOVA
tests across all four groups. HTN refers to the self-reported patients, those with the use of antihypertensive drugs, or detected with undiagnosed
hypertension; DM refers to self-reported type 2 diabetes or elevated FPG (FPG ≥ 100 mg/dL). Abbreviations: MDRD Modification of diet in renal
disease, CKD-EPI Chronic kidney disease epidemiology collaboration, FPG Fasting plasma glucose, HTN Hypertension.
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http://www.biomedcentral.com/1471-2369/14/253diabetes (diagnosed and undiagnosed) or prediabetes com-
pared with normoglycemia, regardless of CKD stage
and GFR estimating equation. Indeed, around a third
of people with diabetes and 15.0% of those with pre-
diabetes had CKD. Furthermore, microalbuminuria, aTable 4 Risk factors for kidney damage and CKD - multivariab
Albuminuria Decreased G
MDRD Study–estimated C
Age 1.01 (1.01,1.02) 1.10 (1.07,1.12)
Gender (female vs male) 1.62 (1.36,1.92) 0.58 (0.37,0.91)
BMI (kg/m2) 1.07 (1.05,1.10) 1.07 (1.00,1.14)
TG (mg/dL) 1.14 (1.08,1.21) 1.01 (0.80,1.28)
Hypertension 1.70 (1.41,2.04) 2.20 (1.34,3.60)
Diabetes or prediabetes 1.69 (1.42,2.02) 1.48 (0.93,2.36)
Data are multivariable-adjusted odds ratios (95% CI). Hypertension was defined as s
the use of antihypertensive drugs, or by any self-reported history of hypertension. D
FPG (FPG ≥ 100 mg/dL).
Abbreviations: GFR Glomerular filtration rate, MDRD Modification of diet in renal disea
FPG Fasting plasma glucose.marker of endothelial injury and a harbinger for pro-
gression to CKD [27], was present in 23.4% of our
participants with diabetes. Dysglycemia independently
explained 30.3% of the PAR of CKD, while hypertension
explained 44.5%.le logistic regression analysis
FR CKD
KD-EPI–estimated MDRD Study–estimated CKD-EPI–estimated
1.14 (1.12,1.17) 1.02 (1.01,1.03) 1.03 (1.02,1.04)
0.89 (0.63,1.27) 1.48 (1.25,1.75) 1.50 (1.27,1.76)
1.02 (0.97,1.08) 1.08 (1.05,1.10) 1.07 (1.04,1.10)
1.06 (0.89,1.25) 1.14 (1.08,1.20) 1.15 (1.09,1.22)
1.72 (1.18,2.50) 1.70 (1.42,2.03) 1.64 (1.38,1.95)
1.30 (0.91,1.87) 1.65(1.39,1.95) 1.60 (1.36,1.89)
ystolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg,
iabetes or prediabetes referred to self-reported type 2 diabetes or elevated
se, CKD-EPI Chronic kidney disease epidemiology collaboration, TG Triglyceride,
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http://www.biomedcentral.com/1471-2369/14/253The prevalence of albuminuria and CKD was high
among people with diagnosed (28.9%) and undiag-
nosed (28.1%) diabetes and was similar to that found in
recent population-based studies from other parts of Asia
[17,28,29]. The prevalence of CKD among people with
diabetes was, however, lower than that found in many
community-based or primary care studies [15,30,31]. but
higher that that reported in a recent community-based
study in Taiwan [32]. The overall prevalence of CKD ob-
served in our study was similar to that reported in other
North American, European and Asian countries (10.5–
13.1%) [9,30,33,34]. where the increase in CKD has been
attributed to a number of risk factors including diabetes,
hypertension, and age of 60 or greater [35,36].
The high contribution of dysglycemia to the occur-
rence of CKD found in our study reflects the rapid rise
in the burden of diabetes mellitus in China over the re-
cent decades. Of the participants with CKD, 15.2% had
diagnosed diabetes, 11.1% had undiagnosed diabetes and
27.3% had prediabetes. Hitherto, the role of various risk
factors to the occurrence of CKD in developing coun-
tries has not been clearly defined. In China, although
evidence on CKD based on renal biopsies had previously
indicated that primary glomerulonephritis (GN) was the
most common form of renal diseases [37], the latter
condition has declined considerably in the past two de-
cades, while the incidence of diabetic nephropathy has
increased significantly [12]. While it is clear from studies
mainly including Caucasians that diabetes is a strong risk
factor for developing CKD and end-stage renal disease
[8,38], very few studies have examined the contribution
of prediabetes, a more prevalent condition than diabetes,
to the occurrence of CKD. In our study, the prevalence
of CKD in people with prediabetes was lower than the
age-, gender-, ethnicity-adjusted 17.1% observed in the
1999–2006 National Health and Nutrition Examination
Survey (NHANES) in the United States [15]. However,
our prevalence of CKD among people with dysglycemia
was higher than observed in a screening study for diabetes
complications among Chinese from two urban communi-
ties in Shanghai (crude prevalence of CKD was 23.6% in
subjects with diabetes and impaired glucose regulation)
[17]. These differences may be related to demographic
characteristics and the methods of diabetes ascertainment,
as nearly half of diabetes cases in our study were diagnosed
through biochemical testing, while most cases in other
studies were self-reported [39]. Interestingly, people with
prediabetes had a relatively high prevalence of decreased
kidney function, similar to those with diagnosed diabetes,
indicating that the decrease in GFR may start early in the
natural history of diabetes, and may be due to hyperfiltra-
tion state in the early stages of hyperglycemia. Conse-
quently, albuminuria and eGFR may have complementary
roles in screening different age groups, and the use of thesetwo variables together could be proved more efficient at
identifying people at a high risk of progression to kidney
failure [40].
The method of GFR estimation may influence the figures
of CKD prevalence; hence we used two commonly ac-
cepted equations. The prevalence of CKD obtained with
the MDRD Study equation was relatively low compared to
that obtained in other populations [15,39]. However, the
MDRD Study equation is the most widely used equation
worldwide [41,42]. and has been modified and validated for
the Chinese population [9,43]. Though the CKD-EPI equa-
tion is said to be a more accurate tool than the MDRD
equation, it has not been commonly used in the Chinese
population [23,44], and the question on the validity of the
GFR estimation using the CKD-EPI equation in this popu-
lation remains to be answered. Although CKD prevalence
obtained with the CKD-EPI equation were higher CKD
than that based on MDRD Study equation, which is not
consistent with the findings in some previous report [23],
the patterns of CKD prevalence across glycemic categories
and the direction and magnitude relative contribution of
dysglycemia were similar with both GFR estimation equa-
tions, confirming the robust relationship between hypergly-
cemia and CKD.
Our study has some limitations. The cross-sectional
design and the lack of oral glucose –tolerance test made
it challenging to account for the full spectrum of dysgly-
cemia when evaluating the association between glycemic
status and CKD. It is possible that the contribution of
non-diabetic hyperglycemia is in fact higher than what
we observed, as many people with impaired glucose tol-
erance may have been misclassified as having normal
glucose regulation. There may have been some misclassi-
fication of early-stage CKD as a result of the limitations
in GFR estimation and single spot urine measurements.
Some transient albuminuria was also possible, especially
among women who may have urinary tract infections or
are menstruating. The duration of diabetes was unknown
in our study; longer exposure to hyperglycemia could in-
crease the risk for CKD. A prospective follow-up of our
participants is ongoing to further assess the incidence of
CKD in people at different levels of glycemia.
Our study has a number of strengths. First, the study
includes a large and representative sample of the general
population, with a high response rate, and rigorously stan-
dardized methods for data collection with stringent quality
control. Second, we examined the independent contribu-
tion of a large spectrum of hyperglycemia to CKD, includ-
ing non-diabetic range hyperglycemia. Our findings are
very informative, and have important clinical and public
health relevance for early detection, prevention and con-
trol of CKD among Chinese adults. Indeed, the high
CKD prevalence in individuals with dysglycemia regard-
less of their hypertension status suggests that individuals
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http://www.biomedcentral.com/1471-2369/14/253with prediabetes may be an appropriate target group for
CKD screening [45]. Detection of prediabetes may also
make CKD screening more effective, and campaigns to
promote awareness of both kidney damage and decline
in kidney function at this early stage of dysglycemia —
targeted at both physicians and the community — may
be beneficial [46].Conclusions
In summary, dysglycemia appears as a strong, independent
contributor to the burden CKD in the Chinese population
of Shanghai, a findings that will have to be confirmed in
longitudinal studies. In view of the continuous increase of
hyperglycemic conditions in China, and in the context of
a high prevalence of undetected prediabetes/diabetes and
CKD, screening for both prediabetes and diabetes among
people with CKD, and screening for CKD among individ-
uals with prediabetes or diabetes, should be considered,
as is currently recommended by the American Diabetes
Association [47].
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